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Strict control of systolic blood pressure is known to slow
progression of chronic kidney disease (CKD). Here we
compared audit-based education (ABE) to guidelines and
prompts or usual practice in lowering systolic blood pressure
in people with CKD. This 2-year cluster randomized trial
included 93 volunteer general practices randomized into
three arms with 30 ABE practices, 32 with guidelines and
prompts, and 31 usual practices. An intervention effect on
the primary outcome, systolic blood pressure, was calculated
using a multilevel model to predict changes after the
intervention. The prevalence of CKD was 7.29% (41,183 of
565,016 patients) with all cardiovascular comorbidities more
common in those with CKD. Our models showed that the
systolic blood pressure was significantly lowered by
2.41mmHg (CI 0.59–4.29mmHg), in the ABE practices with
an odds ratio of achieving at least a 5mmHg reduction in
systolic blood pressure of 1.24 (CI 1.05–1.45). Practices
exposed to guidelines and prompts produced no significant
change compared to usual practice. Male gender, ABE,
ischemic heart disease, and congestive heart failure were
independently associated with a greater lowering of systolic
blood pressure but the converse applied to hypertension and
age over 75 years. There were no reports of harm. Thus,
individuals receiving ABE are more likely to achieve a lower
blood pressure than those receiving only usual practice. The
findings should be interpreted with caution due to the wide
confidence intervals.
Kidney International advance online publication, 27 March 2013;
doi:10.1038/ki.2013.96
KEYWORDS: blood pressure; clinical trial; glomerular filtration rate;
hypertension; kidney disease; quality of health care
Chronic kidney disease (CKD) can be managed in primary care
Internationally, the management of stages 1–3 CKD is carried
out in primary care; however, there is scope to improve the
coordination and quality of care.1–3 CKD is more common
with increasing age, and in females but the proportion of
males increases with declining renal function;4,5 with males
more likely to develop proteinuria.6 CKD differs across
ethnic groups,7,8 and with increased deprivation.9 It is also
associated with heart disease,10 heart failure, hypertension
(HT), and diabetes.11 Intervention in CKD is needed because
untreated CKD associated with an increased risk of cardi-
ovascular morbidity and mortality,12–14 hospitalization,15 and
progression to renal failure.16,17 Strict control of systolic
blood pressure (SBP) is known to slow progression;18,19 and
may be cost effective.20,21 CKD was added to the UK’s pay-
for-performance (P4P) (Quality Outcomes Framework)
scheme for primary care in April 2006. This scheme uses
routine data to determine the level of case ascertainment, on
a disease register, and sets financially incentivized quality
indicators. The CKD indicator includes a treatment target of
keeping blood pressure (BP) below 140/85mmHg
preferentially using angiotensin-modulating drugs in the
presence of proteinuria.
Uncertainty about CKD and its management
Despite all that is known about CKD, there is uncertainty
about how to improve the quality of care. A systematic review
of interventions in CKD concludes that other than for people
with diabetes, there is a lack of research evidence about how
best to develop services. Primary care clinicians feel they lack
knowledge and confidence in its management. CKD is
usually diagnosed using a four-item formula (age, gender,
serum creatinine, and ethnicity) to estimate glomerular
filtration rate; and from the presence of proteinuria
or albuminuria. The condition has a range of different
underlying pathological and ageing processes leading
some clinicians to speculate that is merely a biochemical
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construction rather than a disease per se.22–24 A Cochrane
review of the use of angiotensin-modulating drugs, the main
recommended treatment, in early CKD reports uncertainty
about their value,25,26 other than for people with CKD and
diabetes.27 In addition, a systematic review of interventions
in CKD concludes that again, other than for people with
diabetes, there is a lack of research as to how services to
support management should be developed.28,29
An appropriate quality improvement (QI) intervention
Audit-based education (ABE) is a QI intervention developed
over the last 15 years, which provides education, peer support,
and documents the gap between achievement and guidelines.
This is a complex, non-judgmental, educational intervention
underpinned by the use of information technology to extract
and make comparisons between practices and against
evidence-based guidelines; details in Box 1.30 In observational
studies, this intervention improves the quality of cardiovascular
disease management.31,32 The theoretical basis for this interven-
tion is that audit and feedback, and professional meetings are
known to have small but positive effects on quality.33,34 Any
change that takes place might be explained by control
theory,35 which suggests that this is most likely if feedback is
accompanied by a target or action plan,36 ideally in writing.37
Rationale for the study
A systematic review identified very few studies involving QI
interventions to lower SBP in CKD, and those there were
largely focused on high-risk groups, including ethnic
minorities with interventions largely carried out by nurses
and pharmacists.18 A subsequent diagnostic analysis, using
focus groups, found primary care teams are uncertain about
whether CKD was really a disease, disliked its diagnosis based
on estimate glomerular filtration rate and found it very
difficult to explain the condition to patients.22
Aim
We carried out this study to determine whether ABE might
be effective in addressing the quality gap in CKD manage-
ment using reduction in SBP as the primary outcome
measure of improved management.
RESULTS
Recruitment and sample size
We over-recruited into the trial, anticipating that more
practices would drop out than did. The registered practice
populations consisted of 691,504 registered people. The mean
age of the population was 41.1 years (s.d. 22.36 years) and the
mean index of multiple deprivation 17.4 (s.d. 13.66,
Supplementary Table S6 online). There were 30 practices in
the ABE arm with a mean list size of 9082; 32 practices in the
guidelines and prompts (G&P) arm with a mean list size of
6992; and 31 practices in usual practice (UP) arm with a
mean list size of 6300 (Table 1). During the course of the
study, 10.6% of the population died or left the trial practices.
Ethnicity was recorded for around half the population and
69% of these had white ethnicity (Table 1). There were
statistically significant differences between the population
arms in demographics and proportions with cardiovascular
comorbidities (Supplementary data files online).
Class of CKD by study arm
The crude prevalence of CKD for the trial population (aged
18 years and over) was 9.84% for women, 4.74% for men,
and 7.29% for the population. The age-standardized rates
(based on the 2001 UK National Census) were 9.84% (95%
confidence interval (CI) 9.73–9.95%), 3.69% (95% CI
4.66–4.81%), and 7.29% (95% CI 7.22–7.36%), respectively.
The CKD cases with before and after BP readings, included
in our analysis, (n¼ 23,311) had a mean age of 75.1 years: 75.1
years in the ABE arm (n¼ 9333); 74.7 years in G&P
(n¼ 6871); 75.3 years in the UP arm (n¼ 7107, Table 2).
The mean deprivation score for the CKD cases was 15.8
and ethnicity was recorded for 60.6%; there were statistically
significant differences in these between the study arms. The
Box 1 | Components of audit-based education (ABE)
1. Anonymized extraction of the data set required to report any whether
there was any quality improvement. The usual components are:
a. Denominator to allow standardization of prevalence.
b. Subset of people with the target condition—to create a virtual
disease register.
c. Clinically relevant comorbidities, risk factors, and treatment.
2. Processing that data to make it informative and providing
comparative feedback combined with academic detailing. A key
feature is presenting comparative feedback comparing practices at
twice yearly meetings held within a locality/primary care organiza-
tion. These meetings are called Data Quality Workshops (DQW),
generally locally led with a consultant of the relevant discipline
attending as a specialist resource.
3. In addition to the presentation at the DQW practices are provided
two additional printed aids:
a. ‘Laminate’—a single laminated A4 page summary of the
practice demographics and case ascertainment compared with
others who attended the DQW. This is for the practice notice
board or other prominent location (we recommend wherever
they take their breaks).
b. Workbook—a slide by slide explanation of the DQW
presentation—and what the data means for their practice,
compared with their peers and any evidence-based guidance.
4. Running local searches in the practices to provide lists of patients
that need to be targeted for intervention. These lists are usually
generated by individual GP. Experiential learning is that audit lists
of up to 150 per 10,000 registered patients result in change.
5. Supporting education about the evidence-base and providing
coding or other training is provided as required.
6. Participants have been encouraged to contribute to the future
development of the ABE program.
ABE is an intervention developed over 10 years ago; its aim is to
provide feedback about performance against guidance. ABE includes
feedback about quality compared with peers in a workshop setting
usually led by a local GP with a specialist available as an expert
resource, and also supported by academic detailing. ABE usually also
identified lists of patients within the practices needing intervention.
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proportion of people with HT and stroke was not
significantly different between the arms of the study, but
the proportions of other comorbidities were significantly
different (Table 1). All the cardiovascular comorbidities were
more common in the CKD cases than in the general
population. The prevalence of diabetes was 4.9% in the
practices’ overall adult population and 19.2% in the CKD
cases; HT 15.6% versus 71.4%; heart failure 0.8% versus
5.8%; peripheral vascular disease 0.7% versus 4.0%; cere-
brovascular disease (stroke or transient ischemic attack (TIA)
1.2% versus 6.3% for the overall population and CKD cases
population respectively.
Fall in SBP between study arms
Mean SBP fell by 4.91 (95% CI 4.51–5.32)mmHg in the ABE
arm, by 4.20 (95% CI 3.71–4.68)mmHg in G&P, and 3.71
(95% CI 3.25–4.17)mmHg in UP (Table 3). The fall was
greatest with increasing age, the biggest reduction being in
people over 75 years. Across all age bands the reduction in BP
was greatest in the ABE arm of the study (Figure 1). When we
compared the reduction in the ABE arm with pooled data
from the other two arms the reduction in SBP is 0.96mmHg
(95% CI 0.439–1.429). There was no difference in the time
period between observations between the SBP measures in
the three arms of the study. The median and interquartile
range between the BP readings by study arm were 943 days
(833–1035), 941 days (829–1036), and 937 days (826–1031)
for ABE, G&P, and UP arms, respectively.
A greater proportion of people in the ABE arm (12.3%)
were at target post intervention compared with G&P (9.2%)
and UP (9.3%, Table 4). The proportion of people with a
45mmHg reduction in SBP was 47.1% in ABE, 45.9% in
G&P, and 45.3% in the UP arm. The odds ratio (OR) of
achieving a45mmHg reduction in ABE compared with UP,
was 1.24 (95% CI 1.053–1.450, P¼ 0.010). People with ischemic
heart disease (IHD) also, had an increased OR 1.132 (95% CI
1.01–1.27; P¼ 0.033); whereas people treated with ‘other’
antihypertensives (i.e., non-angiotensin-modulating drugs)
and those over 75 years old had OR suggesting they were
less likely to achieve a45mmHg reduction in SBP (Table 5).
Change in process and outcome measures
Within the ABE arm, there was a greater switch to using
angiotensin-modulating antihypertensive therapy (angioten-
Table 1 | Baseline characteristics of the population in each study arm
Audit-based education Guidelines and prompts Usual practice
All practices
total Statistical test
List sizes for trial practices NPar w2
Trial population
Patients 272,467 (39.4%) 223,730 (32.4%) 195,307 (28.24%) 691,504 (100%) Po0.001
Mean list size 9082 6992 6300 7436
Adult population
Patients 223,847 (39.6%) 181,318 (32.1%) 159,851 (28.29%) 565,016 (100%) Po0.001
Mean list size 7462 5666 5156 6075
Demographics of population
Age (years)
n 272,467 (39.4%) 223,730 (32.4%) 195,307 (28.24%) 691,504 (100%) ANOVA
Mean 41.4 40.1 41.8 41.1 Po0.001
s.d. 22.3 22.2 22.6 22.4
Gender
Female 135,305 (49.7%) 110,600 (49.4%) 98,457 (50.4%) 344,362 (49.8%) Pearson w2
Male 137,162 (50.3%) 113,130 (50.6%) 96,850 (49.6%) 347,142 (50.2%) Po0.001
Multiple deprivation index score
n 250,832 (38.9%) 208,577 (32.3%) 185,651 (28.8%) 645,060 (100%) ANOVA
Mean 16.1 20.5 15.6 17.4 Po0.001
s.d. 13.1 14.7 12.6 13.7
Ethnicity for population Pearson w2
Not recorded or not stated 155,035 (56.9%) 96,946 (43.3%) 104,723 (53.6%) 356,704 (51.6%) Po0.001
White 75,249 (27.6%) 82,851 (37.0%) 71,547 (36.6%) 229,647 (33.2%)
Mixed 2607 (1.0%) 3737 (1.7%) 1483 (0.8%) 7827 (1.1%)
Asian or Asian British 25,088 (9.2%) 26,925 (12.0%) 8289 (4.2%) 60,302 (8.7%)
Black or black British 11,875 (4.4%) 10,306(4.6%) 6857 (3.5%) 29,038 (4.2%)
Chinese or other ethnicity 2613 (1.0%) 2965 (1.3%) 2408 (1.2%) 7986 (1.2%)
Trial practices (n) 272,467 (100.0%) 223,730 (100.0%) 195,307 (100.0%) 691,504 (100.0%)
Comorbidities Pearson w2
Diabetes 10,969 (4.9%) 9465 (5.2) 7322 (4.6) 27,756 (4.9) Po0.001
Hypertension 35,513 (15.9) 27,216 (15.0) 25,680 (16.1) 88,409 (15.6) Po0.001
Heart failure 1659 (0.7) 1581 (0.9) 1313 (0.8) 4553 (0.8) Po0.001
Peripheral vascular disease 1341 (0.6) 1342 (0.7) 1147 (0.7) 3830 (0.7) Po0.001
Ischemic heart disease 8491 (3.8) 6654 (3.7) 6266 (3.9) 21,411 (3.8) Po0.001
Cerebrovascular disease 2472 (1.1) 2302 (1.3) 1994 (1.2) 6768 (1.2) Po0.001
Abbreviation: ANOVA, analysis of variance.
Complete case analysis including deaths and leavers during the trial.
Bold values indicate the total of the three columns to the left.
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sin-converting enzyme inhibitors (ACE) and angiotensin
receptor blockers), and a lower rate of mortality and onset of
cardiovascular disease compared with the other two arms.
6.5% (n¼ 1058) in the ABE arm; 6.9% (n¼ 712) in G&P
arm; and 5.8% (n¼ 623) people were switched to from non-
ACE to ACE antihypertensive medicines. The annualized
incidence of new cardiovascular disease by arm was 2.4%
(n¼ 364), 2.7% (n¼ 285), and 3.0% (n¼ 325) for ABE, G&P,
Table 2 | Baseline characteristics of the CKD cohort with repeat SBP data
Audit-based education Guidelines and prompts Usual practice All practices
total
Statistical test
List sizes for trial practices NPar w2
Trial population
Patients 272,467 223,730 195,307 691,504 Po0.001
Mean list size 9082.2 6991.6 6300.2 7435.5
Adult population
Patients 204,124 159,261 140,822 504,207 Po0.001
Mean list size 6804.1 4976.9 4542.6 5421.6
Demographics of CKD cohort
Age (years)
n 9333 (40.04%) 6871 (29.48%) 7107 (30.49%) 23,311 (100%) ANOVA
Mean 75.08 74.69 75.32 75.04 P¼ 0.079
s.d. 11.85 11.92 11.68 11.82
Gender
Female 6145 (65.84%) 4506 (65.58%) 4760 (66.98%) 15,411 (66.11%) Pearson w2
Male 3188 (34.16%) 2365 (34.42%) 2347 (33.02%) 7900 (33.89%) P¼ 0.023
Multiple Deprivation Index score
n 9333 (40.04%) 6871 (29.48%) 7107 (30.49%) 23,311 (100%) ANOVA
Mean 15.38 17.76 14.38 15.77 Po0.001
s.d. 12.45 13.47 10.61 12.30
Ethnicity for CKD cohort Pearson w2
Not recorded or not stated 4416 (47.32%) 2069 (30.11%) 2701 (38.00%) 9186 (39.41%) Po0.001
White 3878 (41.55%) 3863 (56.22%) 4011 (56.44%) 11,752 (50.41%)
Mixed 45 (0.48%) 85 (1.24%) 27 (0.38%) 157 (0.67%)
Asian or Asian British 565 (6.05%) 550 (8.00%) 143 (2.01%) 1258 (5.40%)
Black or black British 386 (4.14%) 279 (4.06%) 204 (2.87%) 869 (3.73%)
Chinese or other ethnicity 43 (0.46%) 25 (0.36%) 21 (0.30%) 89 (0.38%)
Trial practices (n) 30 (32.26%) 32 (34.41%) 31 (33.33%) 93 (100%)
Comorbidities CKD cohort Pearson w2
Diabetes 1814 (19.44%) 1405 (20.45%) 1263 (17.77%) 4482 (19.23%) Po0.001
Hypertension 6725 (72.06%) 4949 (72.03%) 4979 (70.06%) 16,653 (71.44%) Po0.001
Heart failure 527 (5.65%) 444 (6.46%) 373 (5.25%) 1344 (5.77%) Po0.001
Peripheral vascular disease 347 (3.72%) 296 (4.31%) 293 (4.12%) 936 (4.02%) P¼ 0.001
Ischemic heart disease 1973 (21.14%) 1485 (21.61%) 1428 (20.09%) 4886 (20.96%) P¼ 0.011
Cerebrovascular disease 550 (5.89%) 444 (6.46%) 468 (6.59%) 1462 (6.27%) Po0.001
Abbreviations: ANOVA, analysis of variance; CKD, chronic kidney disease; SBP, systolic blood pressure.
Bold values indicate the total of the three columns to the left.
Table 3 | Change in systolic BP by arm of study
Systolic BP n Mean (mmHg) s.d. (mmHg) s.e.m. (mmHg)
ABE
Before 9333 138.98 17.73 0.18
After 134.06 16.21 0.17
Change 4.91 19.96 0.21
G&P
Before 6871 139.05 18.81 0.23
After 134.85 16.54 0.20
Change 4.20 20.61 0.25
UP
Before 7107 139.37 18.20 0.22
After 135.66 16.42 0.19
Change 3.71 19.81 0.24
Total
Before 23,311 139.12 18.20 0.12
After 134.78 16.38 0.11
Change 4.33 20.12 0.13
Abbreviations: ABE, audit-based education; BP, blood pressure; G&P, guidelines and
prompts; UP, usual practice.
–1.00
0.00
1.00
2.00
3.00
4.00
5.00
6.00
7.00
18–49 50–74 75+
Age (years)
Fa
ll 
in
 m
ea
n
 S
BP
 (m
mH
g)
ABE
G&P
UP
Study arm
Figure 1 | Fall in mean blood pressure (BP) by study arm between
before and after time periods with increasing age. ABE, audit-
based education; G&P, guidelines and prompts; UP, usual practice.
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and UP arms, respectively (w2 P¼ 0.015). Renal function
improved marginally more in the ABE arm, mean differ-
ence 1.99ml/min; compared with an improvement of 1.95
and 1.96ml/min in G&P and UP arms. Median estimate
glomerular filtration rate improved from 53 to 54ml/min.
The mortality by arm was: 5.0% (n¼ 828), 7.8% (n¼ 954),
and 6.6% (n¼ 812) for ABE, G&P, and UP, respectively.
Multilevel model to explore reduction in SBP by study arm
The multilevel models using linear mixed models (LMMs)
showed a statistically significant greater likelihood of low-
ering BP by around 2.4mmHg in the ABE arm of the trial
compared with the UP arm (Table 6). The changes within the
G&P arm compare with UP crossed parity, and were not
significant. The interclass cluster correlation (ICC) value of
0.061 for the model was higher than that (ICCþ 0.03) used
in the sample size calculation reported in our protocol.38
The LMM suggested that ABE lowered SBP by 2.41mm
Hg (95% CI 0.593–4.285, Table 6). Deprivation quartile,
peripheral vascular disease, cerebrovascular accident and
transient ischemic attack, angiotensin-modulating drugs, and
general practice list size were excluded from the models as
they had no significant impact. In addition to ABE, male
gender, IHD, and chronic heart failure were independently
associated with an increased lowering SBP; whereas the
converse effect was found in people with a diagnosis of HT,
and in people treated with non-angiotensin-modulating HT
therapy (non-ACE HT Px), Afro-Caribbean ethnicity, and
Table 4 | Proportion of people reaching BP target by arm
Status afterward
Off target On target Missing Total
Before
(% at target)
After
(% at target)
Difference
(% difference)
Audit-based education
Status before Off target 2327 2376 1167 5870 49.0 61.1 12.0
On target 1267 3258 1317 5842
Missing 531 927 1886 3344
Total 4125 6561 4370 15,056
Guidelines and prompts
Status before Off target 1729 1678 567 3974 50.2 59.5 9.2
On target 1046 2393 663 4102
Missing 410 620 1292 2322
Total 3185 4691 2522 103,98
Usual practice
Status before Off target 1977 1740 654 4371 47.6 56.8 9.3
On target 1084 2287 680 4051
Missing 451 680 1278 2409
Total 3512 4707 2612 10,831
Abbreviations: ABE, audit-based education; BP, blood pressure; G&P, guidelines and prompts; UP, usual practice.
In all, 12.3% more are at target post intervention with ABE, 9.2% with G&P, and 9.3% with UP.
Table 5 | A multilevel logistic model to predict impact of arm of study and other factors on reduction in systolic BP45mmHg
Model performance AIC¼ 11,851 BIC¼ 11,916
Log likelihood¼
 5916 Deviance¼  5916
ROC C
stat¼ 0.625
Random effects:
Groups Name Variance s.d.
National practice ID (Intercept) 0.043 0.206
Fixed effects Estimate s.e. Pr(4|z|) OR Lower 95% CI Upper 95% CI
(Intercept) 1.035 0.127 0.000 2.815 2.193 3.613
Study arms: audit-based education 0.211 0.082 0.010 1.235 1.053 1.450
Study arms: guidelines and prompts 0.098 0.085 0.250 1.103 0.933 1.303
Systolic BP (z scored) 1.193 0.036 o0.001 3.297 3.072 3.539
Gender: male 0.086 0.048 0.071 1.090 0.993 1.198
IHD 0.124 0.058 0.033 1.132 1.010 1.268
Non-angiotensin-modulating antihypertensive
drugs
 0.118 0.052 0.024 0.889 0.802 0.985
Aged over 75  0.288 0.115 0.012 0.750 0.598 0.939
Abbreviations: AIC, Akaike’s information criterion; BIC, Bayesian information criterion; BP, blood pressure; CI, confidence interval; CVA, cerebrovascular accident; IHD, ischemic
heart disease; IMD, index of multiple deprivation; OR, odds ratio; PVD, peripheral vascular disease; ROC C stat, receiver operating characteristic area under the curve statistic;
TIA, transient ischemic attack.
The estimate represents the change in SBP because of study arm or other variable.
Not in the model: IMD quartile, PVD, CVA, TIA, hypertension, heart failure, angiotensin-modulating drugs, Afro-Caribbean ethnicity, general practice list size.
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age over 75 years old. All other age bands were excluded as
they had no significant influence on the model.
DISCUSSION
Principal findings
We found that practitioners exposed to the ABE intervention
are more likely to achieve a greater reduction SBP in their
patients with CKD than those practitioners exposed to UP;
patients in the ABE arm also had a greater chance of
achieving a 45mmHg reduction in SBP. A higher propor-
tion of people in the ABE were changed to angiotensin-
modulating antihypertensive therapy. Also, people in the ABE
arm had fewer cardiovascular events and lower mortality.
There was no evidence that G&P improved care or changed
practice. G&P was not associated with having a significant
reduction in BP. However, the differences between the arms
were small, and much lower than the anticipated reduction.
We also found that use of other antihypertensive therapy (i.e.,
which does not act on the angiotensin system) was associated
with a higher SBP at the end of the trial; and being less likely
to achieve X5mmHg reduction in SBP.
Across all three arms people aged over 75, of Afro-Caribbean
ethnicity, those treated with other (non-angiotensin-modulating)
hypertensive therapy, and with a diagnosis of HT were less
likely to achieve SBP target and reduce SBP. Conversely, ABE,
male gender, IHD, chronic heart failure, and larger practices
were associated with a higher chance of reaching target.
The study was over-recruited, and no practices with-
drew post-randomization. Generally, there was a much
higher prevalence of cerebrovascular disease among people
with CKD.
Implications of the findings
Despite widespread skepticism among practitioners as to the
significance of a CKD diagnosis in older people practices
continued to allow access to their records even if they did not
fully participate in their study arm intervention for the
duration of the study. The participant general practices
appeared willing to join and maintain involvement with
improvement science projects. The reduction in SBP
achieved, although small, under 3mmHg, is likely to have
a significant clinical impact at the population level. Although
this reduction in SBP is small and around a third of that
achieved by treatment with BP lowering therapy, it is known
that at the population level a reduction of 5mmHg produces
a reduction of about 34% in stroke and 21% in IHD.39
The study outcomes should lead practitioners to reflect on
how they treat different patient groups. People with IHD and
chronic heart failure may have been perceived to be at higher
risk and treated more aggressively as a result. There are large
numbers of older people with HT and early CKD many of
whom are female who may not be classified as high risk by
many general practitioners. It is possible that clinicians were
treating these people to the P4P target for HT (SBP of
145mmHg) ignoring their CKD.
Caution should be exercised in the interpretation of these
findings because the CIs around the finding of benefit from
ABE were wide. However, we have demonstrated that ABE
appears to be effective in improving the proportion of people
who achieve a reduction in SBP in primary care. If a similar
effect is confirmed in other studies then we would be more
optimistic of the effectiveness of this intervention. The use of
ACE was promoted within the ABE, and it is possible that
Table 6 | A multilevel model to predict impact of arm of study and other factors on final SBP
Model performance
AIC¼ 87,638 BIC¼ 87,732
Log likelihood
¼  43,806
Deviance
¼ 87,617
REML deviance
¼ 87,612 ICC¼ 0.05
Random effects
Groups Name Variance s.d.
National practice ID (Intercept) 10.878 3.2982
Residual 241.097 15.5273
Fixed effects Estimate Lower 95% CI Upper 95% CI s.e. Pr(|x|40)
(Intercept) 136.565 134.517 138.608 1.063 o0.001
Study arms: audit-based education  2.408  4.285  0.593 0.979 0.012
Study arms: guidelines and prompts  0.925  2.845 0.963 0.984 0.329
Previous systolic BP (z scored) 2.856 2.558 3.164 0.155 o0.001
Gender: male  1.208  1.856  0.559 0.328 0.000
IHD  0.841  1.632  0.049 0.403 0.038
Hypertension 1.359 0.576 2.163 0.401 0.001
Heart failure  1.651  3.117  0.153 0.743 0.026
Non-angiotensin-modulating antihypertensive drugs 1.245 0.434 2.033 0.409 0.002
Afro-Caribbean 2.548 0.635 4.386 0.964 0.009
Aged over 75 2.097 0.546 3.631 0.794 0.008
Abbreviations: AIC, Akaike’s information criterion; BIC, Bayesian information criterion; BP, blood pressure; CI, confidence interval; CVA, cerebrovascular accident; IHD, ischemic
heart disease; ICC, interclass cluster correlation; IMD, index of multiple deprivation; OR, odds ratio; PVD, peripheral vascular disease; REML, restricted maximum likelihood;
TIA, transient ischemic attack.
The estimate represents the change in SBP because of study arm or other variable.
Not in the model: IMD quartile, PVD, CVA, TIA, angiotensin-modulating drugs, general practice list size.
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accounted for the improvement in this arm of the trial.
Although we noted a lower incidence of vascular events and
mortality we have not demonstrated any effect related to
variables rejected from the model.
ABE should be considered as an intervention by those
seeking to improve quality. Sending out academic detailing in
G&P did not appear to change practice. Based on these
findings, it cannot be recommended as a QI strategy.
Comparison with the literature
Although the trial set out to follow the CONSORT
recommendations for randomized controlled trials40 we did
not achieve an even distribution of practice characteristics,
demographic, and comorbidities between study arms. Our
simple block randomization led to there being differences
between the study arms. In a future study, we would use
allocation techniques that achieve a better baseline balance.41
The findings contrast with the findings of a study explor-
ing the variation in incidence of renal replacement therapy.
This study showed that deprivation, non-white ethnicity,
diabetes, and non-achievement of P4P BP target in CKD, were
predictor variables of progression to renal replacement.42
A number of other interventions to improve CKD
management have been reported but these have mainly looked
at their impact on referral rather than on BP management.43
ABE has many of the characteristics of an effective
intervention to improve quality in primary care. It is tailored,
educational, and multifaceted.44 ABE also includes some of
the features of the chronic care model: principally better use
of practice information systems to prepare proactive practice
teams looking to engage and change their quality of service
delivery.45 As more information about how to effect change
becomes available, ABE may be developed further, or
alternatively more likely candidates to drive change may be
adopted.46
Limitations of the method
We did not fully implement ABE as designed. A general
practitioner from the study team was not always present at
the feedback meetings, although where this happened we
tried to at least give individual feedback to that practice. The
majority of attendees at ABE sessions were general practi-
tioners or practice nurses from non-neighboring practices so
the data were fed back to groups from practices who were
meeting for the first time. No ‘local queries’ were run to
identify individual patients requiring intervention for prac-
tices. This important aspect of the intervention was omitted as
a decision of the wider study team who were concerned about
the delays in ethics and in recruitment early in the study.
However, this omission is likely to have lessened the effect of
the intervention: a study of HTmanagement, which compared
audit-based feedback with audit plus details of patients risk
achieved a greater reduction in BP in the latter group.47 We
could also have examined pulse pressure rather than SBP the
latter may be a better predictor of progression in CKD.48
It is possible that changes in end-digit preference in
recording BP may have influenced the recording of BP49 and
repeated measures may result in regression to the mean;50 but
these effects would be expected to have an equal effect on each
arm of the study. Also, the use of only two BP readings, the two
furthest apart in the study period, may have resulted in a loss of
fidelity compared with using more. However, this maximized
the number of people we could include in the study.
Proteinuria is an independent risk factor for cardiovas-
cular risk in CKD and an important effect modifier for
intervention; incomplete recording in people with CKD
meant we could not look at this as an additional variable.51
The power of the analysis was restricted by inter-practice
variation in demographics and cardiovascular comorbidity.
We cannot report yet on the cost effectiveness of ABE as an
intervention but are due to conduct an economic analysis.
Call for further research
Further studies are needed to test the effectiveness of ABE,
perhaps in those people with CKD at highest risk, for
example, those with proteinuria or declining renal function.
It may have been better to have chosen a stepped wedge
design. This would have been ethically simpler, as all arms are
exposed to the same intervention components, and may have
overcome some of the initial delays in recruitment.52
CONCLUSIONS
ABE is a responsive tool to feedback clinically led customized
analyses to improve quality. Here we demonstrate, in the first
trial of an educational intervention underpinned by informa-
tion technology, its potential to improve chronic disease
management in primary care. Further work is required to
determine the generalizability and cost-effectiveness of this
approach.
MATERIALS AND METHODS
Trial design
The quality improvement in CKD (QICKD) trial was a three-arm
cluster randomized study with an intervention period of 2 years,38
approved by research ethics committees and registered with a
clinical trials database.53 The QICKD trial compared two QI
interventions G&P and ABE, with UP.
Setting
We carried out this study in UK primary care. This is a setting that
lends itself to this type of research.54 There is a registration-based
system (patients only register with one practice). Practices are
computerized and electronic patient record (EPR) systems are used
almost universally at the point of care.55 Repeat prescribing data are
complete and electronic links to pathology labs means that test
results are sent directly into practice EPR systems. The UK primary
care P4P scheme rewards quality based on routinely collected data
measures; this in turn has further improved data quality.56 P4P was
first introduced in April 2004, mainly targeted on vascular disease,
with CKD domain added in 2006. The provision of a common data
extraction platform for the different brands of EPR systems
(MIQUEST—Morbidity Information Query and Export Syntax)
make conducting this type of study more straightforward. We
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became involved with CKD in collaboration with renal specialists
interested in identifying people with CKD from general practice
computer records.57 We demonstrated this process was valid58 and
could be used to define the United Kingdom prevalence of CKD.59
The reliability of the diagnosis improving after 2006 when national
quality control system was put in place,60 although there may be
some disparity in creatinine testing.61
Participants
The study participants were health-care professionals who managed
people with CKD in the study practices. Between December 2007
and May 2008, we recruited practices that had the same EPR system
for at least 5 years. Where they changed EPR system we were able to
map patients from one system to the next by anonymous data
linkage based on year of birth, gender, date of registration, and date
of last BP recording. Two rounds of follow-up data collections were
conducted after the intervention: between 1 May 2009 and 29
September 2009; and between 1 April 2010 and 29 July 2010. We
defined the people with CKD as those with an estimated glomerular
filtration rate of o60ml/min (stages 3–5 CKD) based on two
readings at least 90 days apart, whenever available. This fits with
international guidance and smoothes the effect of creatinine
fluctuation.5 We used the Modified Diet in Renal Disease four-
item equation. We restricted our analysis to the group of adults,
people over 18 years old, who fulfilled these criteria between 1 July
2007 and 30 June 2008 7.29% (41,183/565,016; 95% CI 7.22–7.36%)
of the registered population at the start of the study were labeled the
‘CKD cases.’ We included in the analysis people with CKD who had
raised BP, or a diagnosis of HT, or cardiovascular comorbidities
treated using antihypertensive agents.
Interventions
G&P involved the sending of academic detailing,62 printed infor-
mation containing local guidelines on CKD management;63 and
providing access to an information website. This was subsequently
revised to the provision of national guidance following the
publication of CKD guidelines by the National Institute for Health
and Clinical Excellence (NICE). This intervention was designed to
be typical of low cost methods used by the NHS used to prompt
practitioners about quality. ABE (Box 1) was largely implemented as
planned. However, we did not include ‘local queries’, which provide
practices with lists of patients with CKD who are suboptimally
managed; additionally this arm did not receive ABE in addition to
G&P as originally planned, until the second year. In our protocol, we
intended that ABE would be provided in addition to G&P rather
than as an alternative.38
Sample size/power calculation
Our intention was to recruit a sample to finish the study with 25
practices per arm. We identified practices for the study by first
recruiting renal centers willing to take part in the study. This was
because the G&P intervention and ABE arms required the agreement
and participation of the local renal center. We identified renal
centers wishing to participate in Leicester, Birmingham, Cambridge,
southwest London, and Surrey and Sussex. We then recruited
practices in these areas via a range of sources including through
dedicated practice liaison managers, teaching practice networks, and
the local Primary Care Research Networks.
The study was powered to detect a43mmHg difference in SBP
between the group. Using a sample data set of 30 practices, we
estimated that the variation between practice means has a s.d. of
3.77mmHg. Assuming this sample of 30 practices to be represen-
tative of the study practices in terms of their size and number of
CKD patients, we estimated that a sample size of 25 practices per
intervention group was required to detect a difference of 3mmHg at
the 5% level with a power of 80%.
Randomization (including blinding)
A total of 138 practices expressed interest in the project although 16
did not progress to randomization (Figure 2). The reasons for this
were: outside the participating health service locality (n¼ 3); not
consented before we closed recruitment (n¼ 4); withdrew pre-
randomization (n¼ 4). Five practices were allocated to an in-depth
process evaluation arm. A randomization sequence was created in
Microsoft Excel. As practices were recruited a centralized recruit-
ment list was appended on a weekly basis and practices assigned a
unique sequential study number. Newly recruited practices were
then allocated to each of the three study arms at random in blocks of
nine. Once each successive block was filled, the practices were
informed of their allocation. Once the total study practice cohort
recruitment was completed 10 practices from each arm were
randomly allocated per study arm to become questionnaire
practices. These practices received questionnaires about their
confidence and competence in managing CKD. They were not
included in this analysis. Investigators were blinded to the study arm
allocation during analysis, and arms were designated by a number
within the database.
Data
We extracted data from general practice EPR systems using
MIQUEST64 and aggregated the data using well-established
methods.65 We have made our data dictionary, an online lookup
tool, which lists every variable extracted online, publicly available.66
From within the total population (N¼ 951,764), we identified
deaths and leavers from the practices (n¼ 109,701, 11.5%) and
excluded them from the study (Figure 2).
We report the completeness of recording of study variables
(Supplementary data file), demographics, and key comorbidities.
Demographics include: age, index of multiple deprivation score,67 and
ethnicity by study arm. We mapped ethnicity codes to the National
Statistics 5þ 1 categories using a mapping process developed in-
house.68 We additionally captured any coding suggestive of African-
Caribbean ethnicity as this group has a special correction factor in the
formula used to estimate kidney function.69 We also record the
proportion of people at baseline with diabetes having corrected
miscoding, and misdiagnosis;70 as the thresholds for SBP are different
for those with diabetes. We also report the prevalence of five other
cardiovascular co morbidities: IHD, HT, chronic heart failure,
peripheral vascular disease, and cerebrovascular disease.
Outcomes
We report the effect of the intervention arm, compared with UP and
other likely predictor variables on reduction in SBP over the period
of the study. We compared the earliest BP measure in the first year
of the study with the latest recorded in the last. We checked to
see if there was any difference in the time interval between the
earliest and latest SBP reading by arm, reporting median and
interquartile range.
We used ‘Z-score’ to transform BP. This is a standard
methodology for transforming a continuous variable by
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(x-mean(x))/s.d.(x). The resultant variable has a mean of zero and a
s.d. of 1; making SBP more readily combined with variables with
binary values. We also reported incident cases of cardiovascular
disease and HT, and any change in renal function as measured using
estimate glomerular filtration rate.
Statistical methods
We report data using the mean and s.d. and s.e.m. where appropriate.
For non-normally distributed data, we report the median and inter-
quartile range. We quote prevalence as a percentage of the population
aged 18 years and over with 95% CIs. We used Pearson’s w2 to report
any differences in the proportion of people in each study arm.
The secondary outcome measure is a binary outcome, whether a
patient achieved the target BP according to NICE guidelines63 or a
reduction of X 5mmHg we implemented a simple multilevel
logistic regression model,71 using ORs as a measure of effect size.
We developed multilevel models using LMMs fitted using
restricted maximum likelihood; we applied our models to the
whole study arm with CKD and paired BPs. These models were used
to explore the influence of the study arms whilst controlling for age,
deprivation, sex, ethnicity, diabetes, and cardiovascular disease and
differences in practice size between arms. Our approach included
checking for collinearity between variables. This approach was
adopted instead of the originally planned analysis of variance
because of difference in baseline characteristics between the study
arms in particular in the age–sex distribution. These baseline
differences included a difference in practice size, which we have
included in the analysis, as this might affect quality achievement.72
The LMM looked at the impact of potential predictor variables
on reduction of SBP. These LMM were developed using R Statistical
package software 2.14 (www.r-project.org) with the lme4 add in.73
By default, lme4 fits the model using restricting maximum
likelihood. Across all arms of the trial, patients were nested within
their general practice using a random intercept. Model selection was
performed following Maindonald and Braun’s approach, which aims
to maximize the log likelihood, by backward stepwise elimination of
variables.74 We used Markov Chain Monte Carlo methods to
estimate the 95% credible interval for the estimates obtained by this
method; these are broadly similar to confidence intervals, and we
report them as such.
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Practices
Assessed eligibility (n =138)
- Outside participating localities (n =3)
- Withdrew from study (n =4)
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- Process evaluation practices (n =5)
- Questionnaire practices (n =29)
Randomized: 122 practices
Allocated to trial n =93
(no. of patients =69,1504)
Allocated to audit-based
education: n =30
(no. of patients=22,3847;
no in CKD cohort=16,605)
Analysis: n =30
(no. in CKD cohort=15,056)
No. CKD cohort with
before & after SBP=9333
Analysis: n =32
(no. in CKD cohort=10,399)
No. CKD cohort with
before & after SBP=6871
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(no. in CKD cohort=10,833)
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Figure 2 | CONSORT (2010) flow diagram of practice recruitment and exclusion in the quality improvement in chronic kidney disease
(QICKD) trial. SBP, systolic blood pressure.
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